View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 10, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Surgery Partners, Inc.
Entity Central Index Key	0001638833
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		48,818,241

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 55,966	$ 69,699
Accounts receivable, less allowance for doubtful accounts of $30,040 and $29,872, respectively	218,015	220,594
Inventories	29,343	28,777
Prepaid expenses and other current assets	35,879	32,014
Acquisition escrow deposit	10,874	10,871
Total current assets	350,077	361,955
Property and equipment, net	204,669	204,253
Intangible assets, net	45,753	48,023
Goodwill	1,556,504	1,555,204
Investments in and advances to affiliates	35,114	34,980
Restricted invested assets	315	315
Long-term deferred tax assets	81,327	83,793
Other long-term assets	15,974	16,435
Total assets	2,289,733	2,304,958
Current liabilities:
Accounts payable	47,587	49,766
Accrued payroll and benefits	25,560	29,273
Acquisition escrow liability	10,874	10,871
Other current liabilities	83,713	68,993
Current maturities of long-term debt	28,722	27,822
Total current liabilities	196,456	186,725
Long-term debt, less current maturities	1,396,042	1,414,421
Long-term tax receivable agreement liability	122,351	122,351
Other long-term liabilities	75,889	76,266
Non-controlling interests—redeemable	179,389	180,521
Stockholders' equity:
Preferred stock, $0.01 par value, 20,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value, 300,000,000 shares authorized, 48,782,362 shares issued and outstanding at March 31, 2017; 48,488,616 shares issued and outstanding at December 31, 2016	488	485
Additional paid-in capital	321,820	320,543
Retained deficit	(314,105)	(311,351)
Total Surgery Partners, Inc. stockholders' equity	8,203	9,677
Non-controlling interests—non-redeemable	311,403	314,997
Total stockholders' equity	319,606	324,674
Total liabilities and stockholders' equity	$ 2,289,733	$ 2,304,958

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 30,040	$ 29,872
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)	20,000,000	20,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (shares)	300,000,000	300,000,000
Common stock, shares issued (shares)	48,782,362	48,488,616
Common stock, shares outstanding (shares)	48,782,362	48,488,616

Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Income Statement [Abstract]

Revenues

$ 286,183

$ 267,074

Operating expenses:

Salaries and benefits

89,887

86,886

Supplies

71,160

63,662

Professional and medical fees

21,125

19,654

Lease expense

13,626

12,434

Other operating expenses

16,150

14,067

Cost of revenues

211,948

196,703

General and administrative expenses (includes contingent acquisition compensation expense of $2,033 for the quarter ended March 31, 2017)

15,541

12,197

Depreciation and amortization

11,108

9,568

Provision for doubtful accounts

5,675

3,873

Income from equity investments

(1,200)

(758)

Loss (gain) on disposal or impairment of long-lived assets, net

1,196

(206)

Loss on debt refinancing

8,281

Merger transaction and integration costs

337

3,172

Electronic health records incentive income

(141)

(93)

Other (income) expense

(2)

Total operating expenses

244,462

232,794

Operating income

41,721

34,280

Interest expense, net

(25,182)

(22,153)

Income before income taxes

16,539

12,127

Income tax expense

2,117

1,770

Net income

14,422

10,357

Less: Net income attributable to non-controlling interests

(17,176)

(17,547)

Net loss attributable to Surgery Partners, Inc.

$ (2,754)

$ (7,190)

Net loss per share attributable to common stockholders

Basic (in USD per share)

$ (0.06)

$ (0.15)

Diluted (in USD per share)

^[1]

$ (0.06)

$ (0.15)

Weighted average common shares outstanding

Basic (shares)

48,019,652

48,017,226

Diluted (shares)

^[1]

48,019,652

48,017,226

[1]	The impact of potentially dilutive securities for the three months ended March 31, 2017 and 2016 was not considered because the effect would be anti-dilutive in those periods.

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Contingent acquisition expense	$ 2,033	$ 0

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 14,422	$ 10,357
Other comprehensive income	0	0
Comprehensive income	14,422	10,357
Less: Comprehensive income attributable to non-controlling interests	(17,176)	(17,547)
Comprehensive loss attributable to Surgery Partners, Inc.	$ (2,754)	$ (7,190)

Condensed Consolidated Statements of Stockholders' Equity - 3 months ended Mar. 31, 2017 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Deficit	Non-Controlling Interests— Non-Redeemable
Beginning Balance, stockholders' equity (shares) at Dec. 31, 2016	48,488,616	48,488,616
Beginning Balance, stockholders' equity at Dec. 31, 2016	$ 324,674	$ 485	$ 320,543	$ (311,351)	$ 314,997
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	10,636			(2,754)	13,390
Issuance of restricted stock, net of forfeitures (shares)		326,345
Issuance of restricted stock, net of forfeitures	0	$ 3	(3)
Equity-based compensation	634		634
Cancellation of restricted shares (in shares)		(32,599)
Cancellation of restricted shares	(649)		(649)
Acquisition and disposal of shares of non-controlling interests, net	(635)		1,295		(1,930)
Distributions to non-controlling interests—non-redeemable holders	$ (15,054)				(15,054)
Ending Balance, stockholders' equity (shares) at Mar. 31, 2017	48,782,362	48,782,362
Ending Balance, stockholders' equity at Mar. 31, 2017	$ 319,606	$ 488	$ 321,820	$ (314,105)	$ 311,403

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income	$ 14,422	$ 10,357
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	11,108	9,568
Amortization of debt issuance costs and discounts	1,846	1,417
Amortization of unfavorable lease liability	(81)	(108)
Equity-based compensation	634	133
Loss (gain) on disposal or impairment of long-lived assets, net	1,196	(206)
Loss on debt refinancing	0	8,281
Deferred income taxes	1,806	1,485
Provision for doubtful accounts	5,675	3,873
Income from equity investments, net of distributions received	(139)	(372)
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable	(3,433)	(12,546)
Other operating assets and liabilities	1,836	3,362
Net cash provided by operating activities	34,870	25,244
Cash flows from investing activities:
Purchases of property and equipment, net	(6,350)	(11,804)
Payments for acquisitions, net of cash acquired	(275)	(7,049)
Net cash used in investing activities	(6,625)	(18,853)
Cash flows from financing activities:
Principal payments on long-term debt	(45,527)	(396,146)
Borrowings of long-term debt	23,592	501,268
Payments of debt issuance costs	0	(11,909)
Penalty on prepayment of debt	0	(4,900)
Distributions to non-controlling interest holders	(19,262)	(17,513)
Receipts related to ownership transactions with consolidated affiliates	154	94
Restricted stock award vesting	(649)	0
Financing lease obligation	(286)	(171)
Net cash (used in) provided by financing activities	(41,978)	70,723
Net (decrease) increase in cash and cash equivalents	(13,733)	77,114
Cash and cash equivalents at beginning of period	69,699	57,933
Cash and cash equivalents at end of period	$ 55,966	$ 135,047

Organization	3 Months Ended
Organization	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Surgery Partners, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), was formed April 2, 2015, as a holding company for the purpose of facilitating an initial public offering (the “IPO”) of shares of common stock. Prior to September 30, 2015, the Company conducted business through Surgery Center Holdings, Inc. and its subsidiaries. Surgery Center Holdings, LLC was and is the sole indirect owner of the equity interests of Surgery Center Holdings, Inc. and has no other material assets. On October 1, 2015, the Company completed its IPO of 14,285,000 shares of common stock at an offering price of $19.00 per share. On September 30, 2015, Surgery Partners, Inc. became the direct parent and sole member of Surgery Center Holdings, LLC (the "Reorganization"). In the Reorganization, all of the equity interests held by the pre-IPO owners of Surgery Center Holdings, LLC were contributed to Surgery Partners, Inc. in exchange for 33,871,990 shares of common stock of Surgery Partners, Inc. and certain rights to additional payments under a tax receivable agreement. After giving effect to the Reorganization, Surgery Partners, Inc. is a holding company, and its sole material asset is an equity interest in Surgery Center Holdings, LLC. As of March 31, 2017, the Company owned and operated a national network of surgical facilities and ancillary services in 29 states. The surgical facilities, which include ambulatory surgery centers ("ASCs") and surgical hospitals, primarily provide non-emergency surgical procedures across many specialties, including, among others, gastroenterology ("GI"), general surgery, ophthalmology, orthopedics and pain management. The Company's surgical hospitals provide services such as diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy and wound care. Ancillary services are comprised of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, optical services and specialty pharmacy services. As of March 31, 2017, the Company owned or operated a portfolio of 104 surgical facilities, comprised of 99 ASCs and five surgical hospitals. The Company owns these facilities in partnership with physicians and, in some cases, healthcare systems in the markets and communities it serves. The Company owned a majority interest in 74 of the surgical facilities and consolidated 94 of these facilities for financial reporting purposes. In addition, the Company owned or operated a network of 56 physician practices.

Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Significant Accounting Policies

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation.

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2016. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Non-Controlling Interests

The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the condensed consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the condensed consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the condensed consolidated statements of cash flows.

The condensed consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control.

Non-Controlling Interests — Redeemable. Each of the partnerships and limited liability companies through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement. In certain circumstances, the partnership and operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physicians’ ownership if certain adverse regulatory events occur, such as it becoming illegal for the physicians to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. The non-controlling interests - redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.

A summary of activity related to the non-controlling interests—redeemable follows (in thousands):



Balance at December 31, 2016	$	180,521
Net income attributable to non-controlling interests—redeemable	3,786
Acquisition and disposal of shares of non-controlling interests, net—redeemable	(710		)
Distributions to non-controlling interest —redeemable holders	(4,208		)
Balance at March 31, 2017	$	179,389

Variable Interest Entities

The condensed consolidated financial statements include the accounts of variable interest entities in which the Company is the primary beneficiary under the provisions of Accounting Standards Codification Topic ("ASC") 810, Consolidation. As of both March 31, 2017 and December 31, 2016, the variable interest entities include five surgical facilities, three anesthesia practices and two physician practices. The Company has the power to direct the activities that most significantly impact the variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses of these entities should they occur. As of March 31, 2017 and December 31, 2016, the condensed consolidated balance sheets of the Company included total assets of $96.7 million and $99.5 million, respectively, and total liabilities of $12.0 million and $10.7 million, respectively, related to the Company's variable interest entities.

Equity Method Investments

The Company has non-consolidating investments in surgical facilities and management companies that own or manage surgical facilities. These investments are accounted for using the equity method of accounting. The total amount of these investments included in investments in and advances to affiliates in the condensed consolidated balance sheets was $35.1 million and $35.0 million as of March 31, 2017 and December 31, 2016, respectively.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All adjustments are of a normal, recurring nature. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), inputs other than quoted prices in active markets that are either directly or indirectly observable (Level 2), or unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions (Level 3), depending on the nature of the item being valued.

The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values.

A summary of the carrying amounts and fair values of the Company's long-term debt follows (in thousands):



	Carrying Amount				Fair Value
	March 31, 2017		December 31, 2016		March 31, 2017		December 31, 2016

2014 First Lien Credit Agreement, net of debt issuance and discount	$	910,584	$	911,784	$	920,264	$	917,528
Senior Unsecured Notes, net of debt issuance and discount	$	388,511	$	387,942	$	409,393	$	412,189

The fair values of the 2014 First Lien Credit Agreement and Senior Unsecured Notes, as defined in Note 3 on Long-Term Debt, were based on a Level 2 computation using quoted prices for identical liabilities in inactive markets at March 31, 2017 and December 31, 2016, as applicable. The carrying amounts related to the Company's other long-term debt obligations approximate their fair values.

The Company maintains a supplemental executive retirement savings plan (the "SERP") for certain executive officers. The SERP is a non-qualified deferred compensation plan for eligible executive officers and other key employees of the Company that allows participants to defer portions of their compensation. The fair value of the SERP asset and liability was based on a quoted market price, or a Level 1 computation. As of March 31, 2017 and December 31, 2016, the fair value of the assets in the SERP were $1.8 million and $1.7 million, respectively, and were included in other long-term assets in the condensed consolidated balance sheets. The Company had a liability related to the SERP of $1.8 million and $1.7 million as of each of March 31, 2017 and December 31, 2016, respectively, which was included in other long-term liabilities in the condensed consolidated balance sheets.

Revenues

The Company recognizes revenues in the period in which the services are performed. Patient service revenues and receivables from third-party payors are recorded net of estimated contractual adjustments and allowances, which the Company estimates based on the historical trend of its cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.

A summary of revenues by service type as a percentage of total revenues follows:



	Three Months Ended March 31,
	2017		2016
Patient service revenues:
Surgical facilities revenues	89.6	%	91.3	%
Ancillary services revenues	8.8	%	6.6	%
	98.4	%	97.9	%
Other service revenues:
Optical services revenues	1.0	%	1.4	%
Other	0.6	%	0.7	%
	1.6	%	2.1	%
Total revenues	100.0	%	100.0	%

Patient service revenues. The fee charged for healthcare procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient’s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized on the date of service, net of estimated contractual adjustments and discounts from third-party payors, including Medicare and Medicaid. Changes in estimated contractual adjustments and discounts are recorded in the period of change. During the three months ended March 31, 2017, the Company recognized an increase to patient service revenues as a result of changes in estimates to third-party settlements related to prior years of approximately $378,000.

The following table sets forth patient service revenues by type of payor and as a percentage of total patient service revenues for the Company's consolidated surgical facilities (dollars in thousands):



	Three Months Ended March 31,
	2017				2016
	Amount		%		Amount		%
Patient service revenues:
Private insurance	$	139,003	49.4	%	$	132,215	50.5	%
Government	116,878		41.5	%	105,803		40.5	%
Self-pay	6,071		2.2	%	3,713		1.4	%
Other	19,694		6.9	%	19,829		7.6	%
Total patient service revenues	$	281,646	100.0	%	$	261,560	100.0	%
Other service revenues:
Optical service revenues	$	2,821			$	3,624
Other revenues	1,716				1,890
Total net revenues	$	286,183			$	267,074

Other service revenues. Optical service revenues consist of product sales from the Company's optical laboratories as well as handling charges billed to the members of the Company's optical products purchasing organization.. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company's optical laboratories manufacture and distribute corrective lenses and eyeglasses to ophthalmologists and optometrists. Revenue is recognized when product is shipped, net of allowance for discounts.

Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which services are rendered.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.

Accounts Receivable and Allowances for Contractual Adjustments and Doubtful Accounts

Accounts receivable are recorded net of contractual adjustments and allowances for doubtful accounts to reflect accounts receivable at net realizable value. Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. As of March 31, 2017, the Company had a net third-party Medicaid settlements liability of $503,000 compared to a net third-party Medicaid settlements receivable of $454,000 at December 31, 2016.

The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not significant. The Company's policy is to collect co-payments and deductibles prior to providing medical services. It is also the Company's policy to verify a patient’s insurance 72 hours prior to the patient’s procedure. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients.

The Company analyzes accounts receivable at each of its facilities to ensure the proper aged category and collection assessment. At a consolidated level, the Company's policy is to review accounts receivable aging, by facility, to determine the appropriate allowance for doubtful accounts. Patient account balances are reviewed for delinquency based on contractual terms. This review is supported by an analysis of the actual revenues, contractual adjustments and cash collections received. An account balance is written off only after the Company has pursued collection with legal or collection agency assistance or otherwise has deemed an account to be uncollectible.

The receivables related to the Company's optical products purchasing organization are recognized separately from patient accounts receivable, as discussed above, and are included in other current assets in the condensed consolidated balance sheets. Such receivables were $8.9 million and $7.0 million at March 31, 2017 and December 31, 2016, respectively.

Inventories

Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.

Prepaid Expenses and Other Current Assets

A summary of prepaid expenses and other current assets follows (in thousands):



	March 31, 2017		December 31, 2016

Prepaid expenses	$	14,024	$	11,158
Receivables - optical product purchasing organization	8,936		7,042
Insurance recoveries	2,315		2,476
Other current assets	10,604		11,338
Total	$	35,879	$	32,014

Property and Equipment

Property and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally three to five years for computers and software and five to seven years for furniture and equipment. Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized.

A summary of property and equipment follows (in thousands):



	March 31, 2017			December 31, 2016

Land	$	8,082		$	8,082
Buildings and improvements	120,443			118,172
Furniture and equipment	14,959			14,670
Computer and software	30,600			29,902
Medical equipment	119,907			117,418
Construction in progress	2,164			2,396
Property and equipment, at cost	296,155			290,640
Less: Accumulated depreciation	(91,486		)	(86,387		)
Property and equipment, net	$	204,669		$	204,253

The Company also leases certain facilities and equipment under capital leases. Assets held under capital leases are stated at the present value of minimum lease payments at the inception of the related lease. Such assets are depreciated on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset. The carrying values of assets under capital lease were $16.4 million and $15.4 million as of March 31, 2017 and December 31, 2016, respectively, net of accumulated depreciation of $11.4 million and $11.6 million, respectively.

Intangible Assets

The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the condensed consolidated statements of operations over the commitment period of the contract, generally three to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the condensed consolidated statements of operations over the service lives of the agreements, ranging from 2 to 20 years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the condensed consolidated statements of operations over the estimated lives of the relationships, ranging from three to ten years.

A summary of the activity related to intangible assets for the three months ended March 31, 2017 follows (in thousands):



	Physician Income Guarantees			Management Rights			Non-Compete Agreements			Certificates of Need		Customer Relationships			Other			Total Intangible Assets

Balance at December 31, 2016	$	813		$	21,290		$	16,457		$	3,780	$	3,704		$	1,979		$	48,023
Additions	175			—			—			14		—			—			189
Recruitment expense	(142		)	—			—			—		—			—			(142		)
Amortization	—			(433		)	(1,414		)	—		(275		)	(195		)	(2,317		)
Balance at March 31, 2017	$	846		$	20,857		$	15,043		$	3,794	$	3,429		$	1,784		$	45,753

Goodwill

Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.

A summary of activity related to goodwill for the three months ended March 31, 2017 follows (in thousands):



Balance at December 31, 2016	$	1,555,204
Acquisitions	11
Purchase price adjustments	1,289
Balance at March 31, 2017	$	1,556,504

Impairment of Long-Lived Assets, Goodwill and Intangible Assets

The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist in accordance with Accounting Standards Codification (ASC) 350, Intangibles- Goodwill and Other. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value. The cash flow projection and fair value represents management’s best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation. The Company tests its goodwill and intangible assets for impairment at least annually, or more frequently if certain indicators arise.

Restricted Invested Assets

Restricted invested assets of $315,000 as of both March 31, 2017 and December 31, 2016 were related to a requirement under the operating lease agreement at the Company's Chesterfield, Missouri facility. In accordance with the provisions of the lease agreement, the Company has a deposit with the landlord that shall be held as security for performance under the Company's covenants and obligations within the agreement through January 2024.

Other Long-Term Assets

A summary of other long-term assets follows (in thousands):



	March 31, 2017		December 31, 2016

Notes receivable	$	704	$	716
Deposits	3,812		4,196
Assets of SERP	1,834		1,725
Debt issuance costs	1,343		1,488
Insurance recoverable	6,835		6,835
Other	1,446		1,475
Total	$	15,974	$	16,435

Other Current Liabilities

A summary of other current liabilities follows (in thousands):



	March 31, 2017		December 31, 2016

Interest payable	$	27,592	$	19,206
Current taxes payable	3,104		2,622
Insurance liabilities	6,932		6,625
Third-party settlements	1,137		179
Amounts due to patients and payors	14,636		12,221
Tax receivable agreement liability	999		999
Contingent acquisition compensation liability	6,119		4,589
Other accrued expenses	23,194		22,552
Total	$	83,713	$	68,993

Other Long-Term Liabilities

A summary of other long-term liabilities follows (in thousands):



	March 31, 2017		December 31, 2016

Facility lease obligations	$	52,284	$	52,653
Medical malpractice liability	10,453		10,453
Liability of SERP	1,834		1,725
Unfavorable lease liability	1,590		1,671
Other long-term liabilities	9,728		9,764
Total	$	75,889	$	76,266

The Company has facility lease obligations in connection with the surgical hospital located in Idaho Falls, Idaho and with a radiation oncology building at this facility. The obligation is payable to the lessor of this facility for the land, building and improvements. The current portion of the lease obligation was $1.2 million and $1.1 million at March 31, 2017 and December 31, 2016, respectively, and was included in other current liabilities in the condensed consolidated balance sheets. The total of the facility lease obligations related to the surgical hospital and radiation oncology building in Idaho Falls, Idaho was $49.8 million and $50.0 million at March 31, 2017 and December 31, 2016, respectively.

Additionally, the Company has a facility lease obligation in connection with a surgical facility in Ocala, Florida payable to the lessor of this facility for the building. The current portion of the lease obligation was $185,000 and $182,000 at March 31, 2017 and December 31, 2016, respectively, and was included in other current liabilities in the condensed consolidated balance sheets. The total of the facility lease obligations related to the building in Ocala, Florida was $3.7 million at both March 31, 2017 and December 31, 2016.

Operating Leases

The Company leases office space and equipment for its surgical facilities, including surgical facilities under development. The lease agreements generally require the lessee, or the Company, to pay all maintenance, property taxes, utilities and insurance costs. The Company accounts for operating lease obligations and sublease income on a straight-line basis. Contingent obligations of the Company, as defined by each lease agreement, are recognized when specific contractual measures have been met, typically the result of an increase in the Consumer Price Index. Lease obligations paid in advance are recorded as prepaid rent and included in prepaid expenses and other current assets on the condensed consolidated balance sheets. The difference between actual lease payments and straight-line lease expense over the initial lease term, excluding optional renewal periods, is recorded as deferred rent and included in other current liabilities and other long-term liabilities on the condensed consolidated balance sheets.

Equity-Based Compensation

Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. The Company applies the Black-Scholes-Merton method of valuation in determining share-based compensation expense for option awards.

The Company’s policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. In connection with the Reorganization, the Company’s board of directors and stockholders adopted the Surgery Partners, Inc. 2015 Omnibus Incentive Plan from which the Company’s future equity-based awards will be granted.

Professional, General and Workers' Compensation Insurance

The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional and general insurance coverage is on a claims-made basis. Workers' compensation insurance is on an occurrence basis.

The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers compensation claims which relate to (i) claims made during the policy period, which are offset by insurance recoveries and (ii) an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates. The reserves are estimated using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the condensed consolidated balance sheets. Total professional, general and workers' compensation claim liabilities as of March 31, 2017 and December 31, 2016 are $13.5 million and $13.8 million, respectively. The balance includes expected insurance recoveries of $9.2 million and $9.3 million as of March 31, 2017 and December 31, 2016, respectively.

Income Taxes and Tax Receivable Agreement

The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a net operating loss carryforward exists, the Company makes a determination as to whether that net operating loss carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances.

The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2013 or state income tax examinations for years prior to 2012.

As part of the Reorganization that was effective September 30, 2015, the Company entered into a Tax Receivable Agreement (“TRA”) under which generally the Company will be required to pay to its stockholders as of immediately prior to the IPO 85% of the cash savings, if any, in U.S. federal, state or local tax that the Company actually realizes (or is deemed to realize in certain circumstances) as a result of (i) certain tax attributes, including NOLs, capital losses, charitable deductions, alternative minimum tax credit carryforwards and federal and state tax credits of Surgery Partners, Inc. and its affiliates relating to taxable years ending on or before the date of the Reorganization (calculated by assuming the taxable year of the relevant entity closes on the date of the Reorganization) that are or become available to the Company and its wholly-owned subsidiaries as a result of the Reorganization, and (ii) tax benefits attributable to payments made under the TRA, together with interest accrued at a rate of LIBOR plus 300 basis points from the date the applicable tax return is due (without extension) until paid.

The amounts payable under the TRA will vary depending upon a number of factors, including the amount, character and timing of the taxable income of Surgery Partners, Inc. in the future. The Company estimates the total amounts payable to be approximately $123.4 million, if the tax benefits of related deferred tax assets are ultimately realized. The amounts payable were recognized during 2015 in conjunction with the release of the Company's valuation allowance recorded against the deferred tax assets.

The Company and its subsidiaries file a consolidated federal income tax return. The partnerships, limited liability companies, and certain non-consolidated physician practice corporations file separate income tax returns. The Company's allocable portion of each partnership's and limited liability company's income or loss is included in taxable income of the Company. The remaining income or loss of each partnership and limited liability company is allocated to the other owners.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, "Revenue from Contracts with Customers," which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU was originally set to be effective for fiscal years beginning after December 15, 2016, and early adoption was not permitted. In July 2015, the FASB deferred the effective date for the standard to be effective for fiscal years beginning after December 15, 2017. The FASB will now permit companies to early adopt within one year of the new effective date. The Company will adopt this ASU on January 1, 2018 and currently plans to adopt using the full retrospective method. The Company continues to assess the impact of this ASU on its condensed consolidated financial position, results of operations, cash flows and financial disclosures but anticipate the most significant change will be how the estimate for the allowance for doubtful accounts will be recognized under the new standard.

In February 2016, the FASB issued ASU 2016-02, “Leases,” which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. The Company believes the primary effect of adopting the new standard will be to record right-of-use assets and obligations for current operating leases.

In March 2016, the FASB issued ASU 2016-07, “Investments- Equity Method and Joint Ventures,” which allows investments that now meet equity method treatment that were previously accounted for under a different method to apply the equity method prospectively from the date the investment qualifies for equity method treatment. ASU 2016-07 is effective prospectively for fiscal years beginning after December 15, 2016, including interim periods within those years. Early adoption is permitted. The Company adopted this ASU on January 1, 2017. The adoption of this ASU did not have a material impact on the Company's condensed consolidated financial position, results of operations, cash flows and financial disclosures.

In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which clarifies the classification of certain cash receipts and cash payments on the statement of cash flows. ASU 2016-15 is effective retrospectively for fiscal years beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance may have on the condensed consolidated cash flows.

In October 2016, the FASB issued ASU 2016-17, “Interests Held through Related Parties That Are under Common Control,” which modifies existing guidance with respect to how a decision maker that holds an indirect interest in a VIE through a common control party determines whether it is the primary beneficiary of the VIE as part of the analysis of whether the VIE would need to be consolidated. Under the ASU, a decision maker would need to consider only its proportionate indirect interest in the VIE held through a common control party. Previous guidance had required the decision maker to treat the common control party’s interest in the VIE as if the decision maker held the interest itself. As a result of the ASU, in certain cases, previous consolidation conclusions may change. ASU 2016-17 is effective prospectively for fiscal years beginning after December 15, 2016, including interim periods within those years. The Company adopted this ASU on January 1, 2017. The adoption of this ASU did not have a material impact on the Company's condensed consolidated financial position, results of operations, cash flows and financial disclosures.

In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows: Restricted Cash,” which will require the reconciliation of restricted cash in the statement of cash flows. ASU 2016-18 is effective retrospectively for fiscal years beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted. The adoption of this ASU will not have a material impact on the Company's condensed consolidated cash flows.

In January 2017, the FASB issued ASU 2017-01, “Business Combinations – Clarifying the Definition of a Business,” which narrows the definition of a business when evaluating whether transactions should be accounted for as asset acquisition or business combination. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance may have on the condensed consolidated financial position, results of operations and cash flows.

In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of the current goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on the current Step 1). ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those years. Early adoption is permitted for annual and interim periods after January 1, 2017. The Company early adopted this ASU on January 1, 2017. The adoption of ASU 2017-04 only impacts the Company's financial statements in situations where an impairment of a reporting unit’s assets is determined.

Long-Term Debt

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Long-Term Debt

A summary of long-term debt follows (in thousands):



	March 31, 2017			December 31, 2016

2014 Revolver Loan	$	69,000		$	85,000
2014 First Lien Credit Agreement	929,625			932,000
Senior Unsecured Notes	400,000			400,000
Subordinated Notes	1,000			1,000
Notes payable and secured loans	40,808			42,521
Capital lease obligations	14,860			13,996
Less: unamortized debt issuance costs and discount	(30,529		)	(32,274		)
Total debt	1,424,764			1,442,243
Less: Current maturities	28,722			27,822
Total long-term debt	$	1,396,042		$	1,414,421

2014 Revolver Loan

The 2014 Revolver Loan (“Revolver”), entered into on November 3, 2014, is a revolving credit facility used for working capital, acquisitions and development activities and general corporate purposes and matures on November 3, 2019. On October 7, 2015, the Company entered into an amendment to the 2014 First Lien Credit Agreement to increase certain lenders’ commitments under the Revolver from $80.0 million to an aggregate principal amount at any time outstanding not to exceed $150.0 million.

The Company has the option of classifying borrowings under the Revolver as either Alternate Base Rate ("ABR") loans or Eurodollar ("ED") loans. The interest base rate on an ABR loan is equal to the greatest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 0.50% and (c) the adjusted LIBO Rate for a Eurodollar Borrowing with a one-month interest period plus 1.00%. In addition to the base rate, the Company is required to pay a 3.25% margin for ABR loans. The interest base rate on an ED loan is equal to (x) the LIBO Rate for such Eurodollar borrowing in effect for such Interest Period divided by (y) One minus the Statutory Reserves (if any) for such Eurodollar Borrowing for such interest period. In addition to the base rate, the Company is required to pay a 4.25% margin for ED loans. The Company must also pay quarterly commitment fees of 0.50% per annum of the average daily unused amount of the Revolver. As of March 31, 2017, the Company's availability on the Revolver was $77.9 million (including outstanding letters of credit of $3.1 million).

The 2014 First Lien Credit Agreement governs the Revolver and contains various covenants that include limitations on the Company's indebtedness, liens, acquisitions and investments. It additionally includes the requirement that, if triggered, the Company maintain a net leverage ratio within a specified range. As of March 31, 2017, the Company was in compliance with the covenants contained in the 2014 First Lien Credit Agreement.

2014 First Lien Credit Agreement

The 2014 First Lien Credit Agreement (“2014 First Lien”), entered into on November 3, 2014, is a senior secured obligation of Surgery Center Holdings, Inc. and is guaranteed on a senior secured basis by certain subsidiaries of the Company. The 2014 First Lien matures on November 3, 2020. On March 24, 2016, Surgery Center Holdings, Inc. and certain subsidiaries of the Company entered into an amendment to the 2014 First Lien to obtain an incremental term loan in an aggregate principal amount of $80.0 million, which increased the total term loan obligation under the 2014 First Lien to $950.0 million. On September 26, 2016, the Company entered into an amendment to the 2014 First Lien to reduce the interest margins for an ABR loan to 2.75% and for an ED loan to 3.75%.

The Company has the option of classifying the 2014 First Lien as either an ABR loan or an ED loan. The interest base rate on an ABR loan is equal to the greatest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 0.50%, and (c) the Adjusted LIBO Rate for a Eurodollar Borrowing with a one-month interest period plus 1.00%; provided that the base rate shall not be less than 2.00% per annum. In addition to the base rate, the Company is required to pay a 2.75% margin for ABR loans. The interest base rate on an ED loan is equal to (x) the LIBO Rate for such Eurodollar borrowing in effect for such Interest Period divided by (y) One minus the Statutory Reserves (if any) for such Eurodollar Borrowing for such interest period; provided that the rate shall not be less than 1.00% per annum. In addition to the base rate, the Company is required to pay a 3.75% margin for ED loans. Accrued interest is payable in arrears on a quarterly basis. Within five business days after the earlier of (i) 90 days after the end of each fiscal year or (ii) the date on which financial statements have been delivered, the Company is required to make mandatory prepayments in amounts calculated in accordance with the excess cash flow provisions of the 2014 First Lien Credit Agreement. There were no excess cash flow payments required as of March 31, 2017.

The 2014 First Lien Credit Agreement governs the 2014 First Lien and contains various covenants that include limitations on the Company's indebtedness, liens, acquisitions and investments. As of March 31, 2017, the Company was in compliance with the covenants contained in the 2014 First Lien Credit Agreement. The 2014 First Lien is collateralized by substantially all of the assets of the Company.

2014 Second Lien Credit Agreement

The 2014 Second Lien Credit Agreement (“2014 Second Lien”), entered into on November 3, 2014, was prepaid in full on March 31, 2016 as described below. The 2014 Second Lien was a senior secured obligation of Surgery Center Holdings, Inc. and was guaranteed on a senior secured basis by the Company and certain of its subsidiaries. On March 31, 2016, the Company repaid the remaining principal of the 2014 Second Lien of $252.8 million with the proceeds of the issuance of the Senior Unsecured Notes, defined below, of which $1.3 million was accrued interest. In connection with the prepayment, the Company incurred a loss on the extinguishment of debt of $8.3 million which included the write-off of loan costs and the original issue discount and a prepayment penalty for the three months ended March 31, 2016.

Senior Unsecured Notes

Effective March 31, 2016, one of the Company's subsidiaries, Surgery Center Holdings, Inc., issued $400.0 million in gross proceeds of senior unsecured notes due April 15, 2021 (the "Senior Unsecured Notes"). The Senior Unsecured Notes bear interest at the rate of 8.875% per year, payable semi-annually on April 15 and October 15 of each year. The Senior Unsecured Notes are a senior unsecured obligation of Surgery Center Holdings, Inc. and are guaranteed on a senior unsecured basis by each of Surgery Center Holdings, Inc.'s existing and future domestic wholly owned restricted subsidiaries that guarantees the Revolver and the 2014 First Lien.

The Company may redeem up to 35% of the aggregate principal amount of the Senior Unsecured Notes, at any time before April 15, 2018, with the net cash proceeds of certain equity offerings at a redemption price equal to 108.875% of the principal amount to be redeemed, plus accrued and unpaid interest to, but excluding, the date of redemption, provided that at least 50% of the aggregate principal amount of the Senior Unsecured Notes remain outstanding immediately after the occurrence of such redemption and such redemption occurs within 180 days of the date of the closing of any such qualified equity offering.

The Company may redeem the Senior Unsecured Notes, in whole or in part, at any time prior to April 15, 2018 at a price equal to 100.000% of the principal amount of the notes redeemed plus an applicable make-whole premium, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. The Company may redeem the Senior Unsecured Notes, in whole or in part, at any time on or after April 15, 2018, plus accrued and unpaid interest, if any, to the date of redemption plus a redemption price equal to a percentage of the principal amount of the notes redeemed based on the following redemption schedule:



April 15, 2018 to April 14, 2019	106.656	%
April 15, 2019 to April 14, 2020	104.438	%
April 15, 2020 and thereafter	100.000	%

If one of the Company's subsidiaries, Surgery Center Holdings, Inc., experiences a change in control under certain circumstances, it must offer to purchase the notes at a purchase price equal to 101% of the principal amount, plus accrued and unpaid interest to, but excluding, the date of repurchase.

The Senior Unsecured Notes contain customary affirmative and negative covenants, which among other things, limit the Company’s ability to incur additional debt, pay dividends, create or assume liens, effect transactions with its affiliates, guarantee payment of certain debt securities, sell assets, merge, consolidate, enter into acquisitions and effect sale and leaseback transactions.

In connection with the offering of the Senior Unsecured Notes, the Company recorded debt issuance costs of $8.4 million.

Subordinated Notes

The Company has a subordinated debt facility ("Subordinated Notes") of $1.0 million. The Subordinated Notes, owed to H.I.G. Surgery Centers, LLC, mature on August 4, 2017 and bear interest of 17.00% per annum.

Notes Payable and Secured Loans

Certain of the Company’s subsidiaries have outstanding bank indebtedness, which is collateralized by the real estate and equipment owned by the surgical facilities to which the loans were made. The various bank indebtedness agreements contain covenants to maintain certain financial ratios and also restrict encumbrance of assets, creation of indebtedness, investing activities and payment of distributions. At March 31, 2017, the Company was in compliance with its covenants contained in the credit agreement. The Company and its subsidiaries had notes payable to financial institutions of $40.8 million and $42.5 million as of March 31, 2017 and December 31, 2016, respectively. The Company and its subsidiaries also provide a corporate guarantee of certain indebtedness of the Company’s subsidiaries.

Capital Lease Obligations

The Company is liable to various vendors for several equipment leases classified as capital leases. The carrying value of the leased assets was $16.4 million and $15.4 million as of March 31, 2017 and December 31, 2016, respectively.

Earnings Per Share

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Earnings Per Share

Basic and diluted earnings per share are calculated in accordance with ASC 260, Earnings Per Share, based on the weighted-average number of shares outstanding in each period and dilutive stock options, unvested shares and warrants, to the extent such securities exist and have a dilutive effect on earnings per share. The following is a reconciliation of the numerator and denominator of basic and diluted earnings per share for the three months ended March 31, 2017 and 2016 (in thousands except share and per share amounts):



	Three Months Ended March 31,
	2017			2016

Numerator:
Net loss attributable to Surgery Partners, Inc.	$	(2,754	)	$	(7,190	)

Denominator:
Weighted average shares outstanding- basic	48,019,652			48,017,226
Effect of dilutive securities ⁽¹⁾	—			—
Weighted average shares outstanding- diluted	48,019,652			48,017,226

Earnings (loss) per share:
Basic	$	(0.06	)	$	(0.15	)
Diluted ⁽¹⁾	$	(0.06	)	$	(0.15	)

Dilutive securities outstanding not included in the computation of earnings (loss) per share as their effect is antidilutive:
Stock options	851			8,488
Restricted shares	132,485			204,437

⁽¹⁾The impact of potentially dilutive securities for the three months ended March 31, 2017 and 2016 was not considered because the effect would be anti-dilutive in those periods.

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Professional, General and Workers' Compensation Liability Risks The Company is subject to claims and legal actions in the ordinary course of business, including claims relating to patient treatment, employment practices and personal injuries. To cover these claims, the Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional and general insurance coverage is on a claims-made basis. Workers' compensation insurance is on an occurrence basis. Plaintiffs in these matters may request punitive or other damages that may not be covered by insurance. The Company is not aware of any such proceedings that would have a material adverse effect on the Company's business, financial condition or results of operations. Laws and Regulations Laws and regulations governing the Company's business, including those relating to the Medicare and Medicaid programs, are complex and subject to interpretation. These laws and regulations govern every aspect of how the Company's surgical facilities conduct their operations, from licensing requirements to how and whether the Company's facilities may receive payments pursuant to the Medicare and Medicaid programs. Compliance with such laws and regulations can be subject to future government agency review and interpretation as well as legislative changes to such laws. Noncompliance with such laws and regulations may subject the Company to significant regulatory action including fines, penalties, and exclusion from the Medicare, Medicaid and other federal healthcare programs. From time to time, governmental regulatory agencies will conduct inquiries of the Company's practices, including, but not limited to, the Company's compliance with federal and state fraud and abuse laws, billing practices and relationships with physicians. It is the Company's current practice and future intent to cooperate fully with such inquiries. The Company is not aware of any such inquiry that would have a material adverse effect on the Company's business, results of operations or financial condition. Acquired Facilities The Company, through its wholly-owned subsidiaries or controlled partnerships and limited liability companies, has acquired and will continue to acquire surgical facilities with prior operating histories. Such facilities may have unknown or contingent liabilities, including liabilities for failure to comply with healthcare laws and regulations, such as billing and reimbursement, fraud and abuse and similar anti-referral laws. Although the Company attempts to assure that no such liabilities exist, obtain indemnification from prospective sellers covering such matters and institute policies designed to conform centers to its standards following completion of acquisitions, there can be no assurance that the Company will not become liable for past activities that may later be asserted to be improper by private plaintiffs or government agencies. There can be no assurance that any such matter will be covered by indemnification or, if covered, that the liability sustained will not exceed contractual limits or the financial capacity of the indemnifying party. The Company cannot predict whether federal or state statutory or regulatory provisions will be enacted that would prohibit or otherwise regulate relationships which the Company has established or may establish with other healthcare providers or have materially adverse effects on its business or revenues arising from such future actions. Management believes, however, that it will be able to adjust the Company's operations so as to be in compliance with any statutory or regulatory provision as may be applicable. Potential Physician Investor Liability A majority of the physician investors in the partnerships and limited liability companies which operate the Company's surgical facilities carry general and professional liability insurance on a claims-made basis. Each partnership or limited liability company may, however, be liable for damages to persons or property arising from occurrences at the surgical facilities. Although the various physician investors and other surgeons generally are required to obtain general and professional liability insurance with tail coverage that extends beyond the period of any claims-made policies, such individuals may not be able to obtain coverage in amounts sufficient to cover all potential liability. Since most insurance policies contain exclusions, the physician investors will not be insured against all possible occurrences. In the event of an uninsured or underinsured loss, the value of an investment in the partnership interests or limited liability company membership units and the amount of distributions could be adversely affected. Contingent Consideration Pursuant to a purchase agreement dated December 24, 2009 (“the Purchase Agreement”), the Company acquired controlling interests in 36 business entities in various Florida locations which operate freestanding ASCs and provided anesthesia and pain management services (“the 2009 Acquisition”). The Purchase Agreement provided for maximum potential contingent consideration of up to $10.0 million based on operating results subsequent to the acquisition for the period from January 1, 2010 to December 31, 2010. Pursuant to the Purchase Agreement, the contingent consideration is payable as principal under a Subordinated Promissory Note, the form of which was delivered concurrent with the Purchase Agreement. The balance has remained outstanding due to ongoing litigation as a result of a civil claim. The Company has made indemnification claims against the Seller exceeding the amount of the contingent consideration liability, which the Company has a contractual right of offset against. Based on a court order in December 2016, the Company removed the contingent consideration liability on its consolidated balance sheets at December 31, 2016. On April 20, 2017, a settlement was reached between the two parties resulting in the Company receiving $3.9 million of which $2.7 million is to come from the escrow funds set up at the time of purchase and $1.2 million is to come from the seller. The Company expects to record the settlement during the second quarter.

Segment Reporting

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Reporting

A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or "CODM," in deciding how to allocate resources and in assessing performance.

The Company operates in three major lines of business that are also the Company's reportable operating segments - the operation of surgical facilities, the operation of optical services and the operation of ancillary services, which includes physician practices, a diagnostic laboratory and a specialty pharmacy.

During 2016, the Company reassessed its segment reporting and realigned the disclosures to reflect the review and decision making made by the CODM. The purpose of these changes was to replace operating income with adjusted EBITDA as the primary profit/loss metric reviewed by the CODM in making key business decisions and on allocation of resources. The Company has revised the segment disclosures below to replace operating income with adjusted EBITDA and has provided a reconciliation from adjusted EBITDA back to net income in the reported condensed consolidated financial information. These changes had no effect on the Company’s reportable segments, which are presented consistent with prior periods.

The following tables present financial information for each reportable segment (in thousands):



	Three Months Ended March 31,
	2017		2016
Revenues:
Surgical facility services	$	258,149	$	245,670
Ancillary services	25,212		17,780
Optical services	2,822		3,624
Total revenues	$	286,183	$	267,074



	Three Months Ended March 31,
	2017			2016
Segment Adjusted EBITDA:
Surgical facility services	$	48,241		$	45,661
Ancillary services	3,782			3,500
Optical services	776			879
Total segment adjusted EBITDA ⁽¹⁾	$	52,799		$	50,040

General and administrative expenses	$	(15,541	)	$	(12,197	)
Non-cash stock compensation expense	634			133
Contingent acquisition compensation expense	2,033			—
Acquisition related costs	182			450
Total adjusted EBITDA ⁽¹⁾	40,107			38,426

Net income attributable to non-controlling interests	17,176			17,547
Depreciation and amortization	(11,108		)	(9,568		)
Interest and other expense, net	(25,182		)	(22,153		)
Income tax expense	(2,117		)	(1,770		)
Non-cash stock compensation expense	(634		)	(133		)
Contingent acquisition compensation expense	(2,033		)	—
Merger transaction, integration and practice acquisition costs ⁽²⁾	(591		)	(3,917		)
(Loss) gain on disposal or impairment of long-lived assets, net	(1,196		)	206
Loss on debt refinancing	—			(8,281		)
Total net income	$	14,422		$	10,357

⁽¹⁾The above table reconciles adjusted EBITDA by segment to net income as reflected in the unaudited condensed consolidated statements of operations.

When the Company uses the term “Adjusted EBITDA,” it is referring to net income minus (a) net income attributable to non-controlling interests plus (b) depreciation and amortization, (c) interest and other expense, net, (d) income tax expense, (e) non-cash stock compensation expense, (f) contingent acquisition compensation expense, (g) merger transaction, integration and practice acquisition costs, (h) (loss) gain on disposal or impairment of long-lived assets and (i) loss on debt refinancing. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that the Company consolidates for financial reporting purposes. Our operating strategy is to apply a market-based approach in structuring its partnerships with individual market dynamics driving the structure. The Company believes that it is helpful to investors to present Adjusted EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors the Company's portion of Adjusted EBITDA generated by its surgical facilities and other operations.

The Company uses Adjusted EBITDA as a measure of liquidity. It is included because the Company believes that it provides investors with additional information about its ability to incur and service debt and make capital expenditures.

Adjusted EBITDA is not a measurement of financial performance or liquidity under GAAP. It should not be considered in isolation or as a substitute for net income, operating income, cash flows from operating, investing or financing activities, or any other measure calculated in accordance with generally accepted accounting principles. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance and liquidity. The Company's calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

⁽²⁾ This amount includes merger transaction and integration costs of $337,000 and $3.2 million for the three months ended March 31, 2017 and 2016, respectively, and practice acquisition costs of $254,000 and $745,000 for the three months ended March 31, 2017 and 2016, respectively.



	March 31, 2017		December 31, 2016
Assets:
Surgical facility services	$	1,904,858	$	1,914,842
Ancillary services	187,499		184,002
Optical services	23,884		22,478
Total	2,116,241		2,121,322

General and administrative	$	173,492	$	183,636
Total assets	$	2,289,733	$	2,304,958



	Three Months Ended March 31,
	2017		2016
Supplemental Information:
Cash purchases of property and equipment, net:
Surgical facility services	$	4,417	$	9,815
Ancillary services	1,511		560
Optical services	18		77
Total	$	5,946	$	10,452

General and administrative	$	404	$	1,352
Total cash purchases of property and equipment, net	$	6,350	$	11,804

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 20, 2017, a settlement was reached in connection with the litigation discussed above in Note 5, “Contingent Consideration”. The Company expects to record a gain on litigation settlement of $3.9 million during the second quarter. On May 9, 2017, the Company entered into a series of transactions, including (i) an agreement and plan of merger (the “Merger Agreement”) to acquire NSH Holdco, Inc. (“NSH”), an owner and operator of surgical facilities, for approximately $760 million, (ii) an agreement to issue up to 320,000 shares of the Company’s preferred stock, par value $0.01 per share, to be created out of the authorized and unissued shares of preferred stock of the Company, designated as 10.00% Series A Convertible Perpetual Participating Preferred Stock, to BCPE Seminole Holdings LP (the “Investor”) and (iii) an agreement pursuant to which the Company’s controlling stockholder, H.I.G. Surgery Centers, LLC (“H.I.G.”), will sell all of its 26,455,651 shares of common stock of the Company to the Investor at a purchase price per share of $19.00. Following the consummation of the transactions described above, NSH will be an indirect, wholly-owned subsidiary of the Company, and the Investor will be the controlling stockholder of the Company. Also on May 9, 2017, in connection with these transactions, the Company and H.I.G., in its capacity as the Stockholders Representative, agreed to amend that certain Income Tax Receivable Agreement, dated September 30, 2015, by and between the Company, H.I.G. (in its capacity as the Stockholders Representative) and the other parties referred to therein, to provide for a fixed payment schedule pursuant thereto. The amounts payable are related to the projected tax savings to be realized by the Company over the next five years and are not dependent on actual tax savings. Additional information will be included in Item 1.01, “Entry into a Material Definitive Agreement” of a Current Report on Form 8-K describing the transactions.

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as interests in partnerships and limited liability companies controlled by the Company through its ownership of a majority voting interest or other rights granted to the Company by contract to manage and control the affiliate's business. All significant intercompany balances and transactions are eliminated in consolidation. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation of the Company's financial position and results of operations have been included. The Company’s fiscal year ends on December 31 and interim results are not necessarily indicative of results for a full year or any other interim period. The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements as of that date. The information contained in these condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the fiscal year ended December 31, 2016. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Non-Controlling Interests	Non-Controlling Interests The physician limited partners and physician minority members of the entities that the Company controls are responsible for the supervision and delivery of medical services. The governance rights of limited partners and minority members are restricted to those that protect their financial interests. Under certain partnership and operating agreements governing these partnerships and limited liability companies, the Company could be removed as the sole general partner or managing member for certain events such as material breach of the partnership or operating agreement, gross negligence or bankruptcy. These protective rights do not preclude consolidation of the respective partnerships and limited liability companies. Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the condensed consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of non-controlling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the non-controlling interests are identified and presented on the condensed consolidated statements of operations; changes in ownership interests in which the Company retains a controlling interest are accounted for as equity transactions assuming the Company continues to consolidate related entities. Certain transactions with non-controlling interests are classified within financing activities in the condensed consolidated statements of cash flows. The condensed consolidated financial statements of the Company include all assets, liabilities, revenues and expenses of surgical facilities in which the Company has sufficient ownership and rights to allow the Company to consolidate the surgical facilities. Similar to its investments in non-consolidated affiliates, the Company regularly engages in the purchase and sale of ownership interests with respect to its consolidated subsidiaries that do not result in a change of control. Non-Controlling Interests — Redeemable. Each of the partnerships and limited liability companies through which the Company owns and operates its surgical facilities is governed by a partnership or operating agreement. In certain circumstances, the partnership and operating agreements for the Company's surgical facilities provide that the facilities will purchase all of the physicians’ ownership if certain adverse regulatory events occur, such as it becoming illegal for the physicians to own an interest in a surgical facility, refer patients to a surgical facility or receive cash distributions from a surgical facility. The non-controlling interests - redeemable are reported outside of stockholders' equity in the condensed consolidated balance sheets.
Variable Interest Entities	Variable Interest Entities The condensed consolidated financial statements include the accounts of variable interest entities in which the Company is the primary beneficiary under the provisions of Accounting Standards Codification Topic ("ASC") 810, Consolidation. As of both March 31, 2017 and December 31, 2016, the variable interest entities include five surgical facilities, three anesthesia practices and two physician practices. The Company has the power to direct the activities that most significantly impact the variable interest entity's economic performance. Additionally, the Company would absorb the majority of the expected losses of these entities should they occur.
Equity Method Investments	Equity Method Investments The Company has non-consolidating investments in surgical facilities and management companies that own or manage surgical facilities. These investments are accounted for using the equity method of accounting.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Examples include, but are not limited to, estimates of accounts receivable allowances, professional and general liabilities and the estimate of deferred tax assets or liabilities. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All adjustments are of a normal, recurring nature. Actual results could differ from those estimates.
Fair Value of Financial Instruments	The fair values of the 2014 First Lien Credit Agreement and Senior Unsecured Notes, as defined in Note 3 on Long-Term Debt, were based on a Level 2 computation using quoted prices for identical liabilities in inactive markets at March 31, 2017 and December 31, 2016, as applicable. The carrying amounts related to the Company's other long-term debt obligations approximate their fair values. The Company maintains a supplemental executive retirement savings plan (the "SERP") for certain executive officers. The SERP is a non-qualified deferred compensation plan for eligible executive officers and other key employees of the Company that allows participants to defer portions of their compensation. Fair Value of Financial Instruments The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The Company uses fair value measurements based on quoted prices in active markets for identical assets or liabilities (Level 1), inputs other than quoted prices in active markets that are either directly or indirectly observable (Level 2), or unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions (Level 3), depending on the nature of the item being valued. The carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, restricted invested assets and accounts payable approximate their fair values.
Revenues	Other service revenues. Optical service revenues consist of product sales from the Company's optical laboratories as well as handling charges billed to the members of the Company's optical products purchasing organization.. The Company's optical products purchasing organization negotiates volume buying discounts with optical products manufacturers. The buying discounts and any handling charges billed to the members of the buying group represent the revenue recognized for financial reporting purposes. Revenue is recognized as orders are shipped to members. The Company bases its estimates for sales returns and discounts on historical experience and has not experienced significant fluctuations between estimated and actual return activity and discounts given. The Company's optical laboratories manufacture and distribute corrective lenses and eyeglasses to ophthalmologists and optometrists. Revenue is recognized when product is shipped, net of allowance for discounts. Other revenues include management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method, management of surgical facilities in which it does not own an interest, and management services provided to physician practices for which the Company is not required to provide capital or additional assets. The fees derived from these management arrangements are based on a predetermined percentage of the revenues of each facility or practice and are recognized in the period in which services are rendered. Patient service revenues. The fee charged for healthcare procedures performed in surgical facilities varies depending on the type of service provided, but usually includes all charges for usage of an operating room, a recovery room, special equipment, medical supplies, nursing staff and medications. The fee does not normally include professional fees charged by the patient’s surgeon, anesthesiologist or other attending physician, which are billed directly by such physicians to the patient or third-party payor. However, in several surgical facilities, the Company charges for anesthesia services. Ancillary service revenues include fees for patient visits to the Company's physician practices, pharmacy services and diagnostic tests ordered by physicians. Patient service revenues are recognized on the date of service, net of estimated contractual adjustments and discounts from third-party payors, including Medicare and Medicaid. Changes in estimated contractual adjustments and discounts are recorded in the period of change. Revenues The Company recognizes revenues in the period in which the services are performed. Patient service revenues and receivables from third-party payors are recorded net of estimated contractual adjustments and allowances, which the Company estimates based on the historical trend of its cash collections and contractual write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company maintains its cash and cash equivalent balances at high credit quality financial institutions.
Accounts Receivable and Allowances for Contractual Adjustments and Doubtful Accounts	Accounts Receivable and Allowances for Contractual Adjustments and Doubtful Accounts Accounts receivable are recorded net of contractual adjustments and allowances for doubtful accounts to reflect accounts receivable at net realizable value. Accounts receivable consists of receivables from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, employers and patients. Management recognizes that revenues and receivables from government agencies are significant to the Company's operations, but it does not believe that there is significant credit risk associated with these government agencies. Concentration of credit risk with respect to other payors is limited because of the large number of such payors. As of March 31, 2017, the Company had a net third-party Medicaid settlements liability of $503,000 compared to a net third-party Medicaid settlements receivable of $454,000 at December 31, 2016. The Company recognizes that final reimbursement of accounts receivable is subject to final approval by each third-party payor. However, because the Company has contracts with its third-party payors and also verifies insurance coverage of the patient before medical services are rendered, the amounts that are pending approval from third-party payors are not significant. The Company's policy is to collect co-payments and deductibles prior to providing medical services. It is also the Company's policy to verify a patient’s insurance 72 hours prior to the patient’s procedure. Patient services of the Company are primarily non-emergency, which allows the surgical facilities to control the procedures for which third-party reimbursement is sought and obtained. The Company does not require collateral from self-pay patients. The Company analyzes accounts receivable at each of its facilities to ensure the proper aged category and collection assessment. At a consolidated level, the Company's policy is to review accounts receivable aging, by facility, to determine the appropriate allowance for doubtful accounts. Patient account balances are reviewed for delinquency based on contractual terms. This review is supported by an analysis of the actual revenues, contractual adjustments and cash collections received. An account balance is written off only after the Company has pursued collection with legal or collection agency assistance or otherwise has deemed an account to be uncollectible. The receivables related to the Company's optical products purchasing organization are recognized separately from patient accounts receivable, as discussed above, and are included in other current assets in the condensed consolidated balance sheets.
Inventories	Inventories Inventories, which consist primarily of medical and drug supplies, are stated at the lower of cost or market value. Cost is determined using the first-in, first-out method.
Property and Equipment	Property and Equipment Property and equipment are stated at cost or, if obtained through acquisition, at fair value determined on the date of acquisition. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets, generally three to five years for computers and software and five to seven years for furniture and equipment. Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful life of the assets. Routine maintenance and repairs are expensed as incurred, while expenditures that increase capacities or extend useful lives are capitalized. The Company also leases certain facilities and equipment under capital leases. Assets held under capital leases are stated at the present value of minimum lease payments at the inception of the related lease. Such assets are depreciated on a straight-line basis over the lesser of the lease term or the remaining useful life of the leased asset.
Goodwill and Intangible Assets	Intangible Assets The Company has indefinite-lived intangible assets related to the certificates of need held in jurisdictions where certain of its surgical facilities are located. The Company also has finite-lived intangible assets related to physician guarantee agreements, non-compete agreements, management agreements and customer relationships. Physician income guarantees are amortized into salaries and benefits costs in the condensed consolidated statements of operations over the commitment period of the contract, generally three to four years. Non-compete agreements and management rights agreements are amortized into depreciation and amortization expense in the condensed consolidated statements of operations over the service lives of the agreements, ranging from 2 to 20 years for non-compete agreements and 15 years for the management rights agreements. Customer relationships are amortized into depreciation and amortization expense in the condensed consolidated statements of operations over the estimated lives of the relationships, ranging from three to ten years. Goodwill Goodwill represents the fair value of the consideration provided in an acquisition over the fair value of net assets acquired and is not amortized. Additions to goodwill include amounts resulting from new business combinations and incremental ownership purchases in the Company's subsidiaries.
Impairment of Long-Lived Assets, Goodwill and Intangible Assets	Impairment of Long-Lived Assets, Goodwill and Intangible Assets The Company evaluates the carrying value of long-lived assets when impairment indicators are present or when circumstances indicate that impairment may exist in accordance with Accounting Standards Codification (ASC) 350, Intangibles- Goodwill and Other. The Company performs an impairment test by preparing an expected undiscounted cash flow projection. If the projection indicates that the recorded amount of the long-lived asset is not expected to be recovered, the carrying value is reduced to estimated fair value. The cash flow projection and fair value represents management’s best estimate, using appropriate and customary assumptions, projections and methodologies, at the date of evaluation. The Company tests its goodwill and intangible assets for impairment at least annually, or more frequently if certain indicators arise.
Operating Leases	Operating Leases The Company leases office space and equipment for its surgical facilities, including surgical facilities under development. The lease agreements generally require the lessee, or the Company, to pay all maintenance, property taxes, utilities and insurance costs. The Company accounts for operating lease obligations and sublease income on a straight-line basis. Contingent obligations of the Company, as defined by each lease agreement, are recognized when specific contractual measures have been met, typically the result of an increase in the Consumer Price Index. Lease obligations paid in advance are recorded as prepaid rent and included in prepaid expenses and other current assets on the condensed consolidated balance sheets. The difference between actual lease payments and straight-line lease expense over the initial lease term, excluding optional renewal periods, is recorded as deferred rent and included in other current liabilities and other long-term liabilities on the condensed consolidated balance sheets.
Equity-Based Compensation	Equity-Based Compensation Transactions in which the Company receives employee and non-employee services in exchange for the Company’s equity instruments or liabilities that are based on the fair value of the Company’s equity securities or may be settled by the issuance of these securities are accounted for using a fair value method. The Company applies the Black-Scholes-Merton method of valuation in determining share-based compensation expense for option awards. The Company’s policy is to recognize compensation expense using the straight line method over the relevant vesting period for units that vest based on time. In connection with the Reorganization, the Company’s board of directors and stockholders adopted the Surgery Partners, Inc. 2015 Omnibus Incentive Plan from which the Company’s future equity-based awards will be granted.
Professional, General and Workers' Compensation Insurance	Professional, General and Workers' Compensation Insurance The Company maintains general liability and professional liability insurance in excess of self-insured retentions through third party commercial insurance carriers in amounts that management believes is sufficient for the Company's operations, although, potentially, some claims may exceed the scope of coverage in effect. The professional and general insurance coverage is on a claims-made basis. Workers' compensation insurance is on an occurrence basis. The Company expenses the costs under the self-insured retention exposure for general and professional liability and workers compensation claims which relate to (i) claims made during the policy period, which are offset by insurance recoveries and (ii) an estimate of claims incurred but not yet reported that are expected to be reported after the policy period expires. Reserves and provisions are based upon actuarially determined estimates. The reserves are estimated using individual case-basis valuations and actuarial analysis. Reserves for professional, general and workers' compensation claim liabilities are determined with no regard for expected insurance recoveries and are presented gross on the condensed consolidated balance sheets.
Income Taxes and Tax Receivable Agreement	Income Taxes and Tax Receivable Agreement The Company uses the asset and liability method to account for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. If a net operating loss carryforward exists, the Company makes a determination as to whether that net operating loss carryforward will be utilized in the future. A valuation allowance is established for certain net operating loss carryforwards when their recoverability is deemed to be uncertain. The carrying value of the net deferred tax assets assumes that the Company will be able to generate sufficient future taxable income in certain tax jurisdictions, based on estimates and assumptions. If these estimates and related assumptions change in the future, the Company may be required to adjust its deferred tax valuation allowances. The Company, or one or more of its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal income tax examinations for years prior to 2013 or state income tax examinations for years prior to 2012.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, "Revenue from Contracts with Customers," which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU was originally set to be effective for fiscal years beginning after December 15, 2016, and early adoption was not permitted. In July 2015, the FASB deferred the effective date for the standard to be effective for fiscal years beginning after December 15, 2017. The FASB will now permit companies to early adopt within one year of the new effective date. The Company will adopt this ASU on January 1, 2018 and currently plans to adopt using the full retrospective method. The Company continues to assess the impact of this ASU on its condensed consolidated financial position, results of operations, cash flows and financial disclosures but anticipate the most significant change will be how the estimate for the allowance for doubtful accounts will be recognized under the new standard. In February 2016, the FASB issued ASU 2016-02, “Leases,” which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. The Company believes the primary effect of adopting the new standard will be to record right-of-use assets and obligations for current operating leases. In March 2016, the FASB issued ASU 2016-07, “Investments- Equity Method and Joint Ventures,” which allows investments that now meet equity method treatment that were previously accounted for under a different method to apply the equity method prospectively from the date the investment qualifies for equity method treatment. ASU 2016-07 is effective prospectively for fiscal years beginning after December 15, 2016, including interim periods within those years. Early adoption is permitted. The Company adopted this ASU on January 1, 2017. The adoption of this ASU did not have a material impact on the Company's condensed consolidated financial position, results of operations, cash flows and financial disclosures. In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments,” which clarifies the classification of certain cash receipts and cash payments on the statement of cash flows. ASU 2016-15 is effective retrospectively for fiscal years beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance may have on the condensed consolidated cash flows. In October 2016, the FASB issued ASU 2016-17, “Interests Held through Related Parties That Are under Common Control,” which modifies existing guidance with respect to how a decision maker that holds an indirect interest in a VIE through a common control party determines whether it is the primary beneficiary of the VIE as part of the analysis of whether the VIE would need to be consolidated. Under the ASU, a decision maker would need to consider only its proportionate indirect interest in the VIE held through a common control party. Previous guidance had required the decision maker to treat the common control party’s interest in the VIE as if the decision maker held the interest itself. As a result of the ASU, in certain cases, previous consolidation conclusions may change. ASU 2016-17 is effective prospectively for fiscal years beginning after December 15, 2016, including interim periods within those years. The Company adopted this ASU on January 1, 2017. The adoption of this ASU did not have a material impact on the Company's condensed consolidated financial position, results of operations, cash flows and financial disclosures. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows: Restricted Cash,” which will require the reconciliation of restricted cash in the statement of cash flows. ASU 2016-18 is effective retrospectively for fiscal years beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted. The adoption of this ASU will not have a material impact on the Company's condensed consolidated cash flows. In January 2017, the FASB issued ASU 2017-01, “Business Combinations – Clarifying the Definition of a Business,” which narrows the definition of a business when evaluating whether transactions should be accounted for as asset acquisition or business combination. ASU 2017-01 is effective for fiscal years beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance may have on the condensed consolidated financial position, results of operations and cash flows. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill (i.e., Step 2 of the current goodwill impairment test) to measure a goodwill impairment charge. Instead, entities will record an impairment charge based on the excess of a reporting unit’s carrying amount over its fair value (i.e., measure the charge based on the current Step 1). ASU 2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those years. Early adoption is permitted for annual and interim periods after January 1, 2017. The Company early adopted this ASU on January 1, 2017. The adoption of ASU 2017-04 only impacts the Company's financial statements in situations where an impairment of a reporting unit’s assets is determined.

Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Rollforward of Non-Controlling Interests - Redeemable

A summary of activity related to the non-controlling interests—redeemable follows (in thousands):



Balance at December 31, 2016	$	180,521
Net income attributable to non-controlling interests—redeemable	3,786
Acquisition and disposal of shares of non-controlling interests, net—redeemable	(710		)
Distributions to non-controlling interest —redeemable holders	(4,208		)
Balance at March 31, 2017	$	179,389

Schedule of Carrying Amounts and Fair Values of Debt

A summary of the carrying amounts and fair values of the Company's long-term debt follows (in thousands):



	Carrying Amount				Fair Value
	March 31, 2017		December 31, 2016		March 31, 2017		December 31, 2016

2014 First Lien Credit Agreement, net of debt issuance and discount	$	910,584	$	911,784	$	920,264	$	917,528
Senior Unsecured Notes, net of debt issuance and discount	$	388,511	$	387,942	$	409,393	$	412,189

Schedule of Revenues by Service Type

A summary of revenues by service type as a percentage of total revenues follows:



	Three Months Ended March 31,
	2017		2016
Patient service revenues:
Surgical facilities revenues	89.6	%	91.3	%
Ancillary services revenues	8.8	%	6.6	%
	98.4	%	97.9	%
Other service revenues:
Optical services revenues	1.0	%	1.4	%
Other	0.6	%	0.7	%
	1.6	%	2.1	%
Total revenues	100.0	%	100.0	%

Schedule of Revenue Sources for Patient Service Revenues



	Three Months Ended March 31,
	2017				2016
	Amount		%		Amount		%
Patient service revenues:
Private insurance	$	139,003	49.4	%	$	132,215	50.5	%
Government	116,878		41.5	%	105,803		40.5	%
Self-pay	6,071		2.2	%	3,713		1.4	%
Other	19,694		6.9	%	19,829		7.6	%
Total patient service revenues	$	281,646	100.0	%	$	261,560	100.0	%
Other service revenues:
Optical service revenues	$	2,821			$	3,624
Other revenues	1,716				1,890
Total net revenues	$	286,183			$	267,074

Schedule of Prepaid Expenses and Other Current Assets

A summary of prepaid expenses and other current assets follows (in thousands):



	March 31, 2017		December 31, 2016

Prepaid expenses	$	14,024	$	11,158
Receivables - optical product purchasing organization	8,936		7,042
Insurance recoveries	2,315		2,476
Other current assets	10,604		11,338
Total	$	35,879	$	32,014

Schedule of Property and Equipment

A summary of property and equipment follows (in thousands):



	March 31, 2017			December 31, 2016

Land	$	8,082		$	8,082
Buildings and improvements	120,443			118,172
Furniture and equipment	14,959			14,670
Computer and software	30,600			29,902
Medical equipment	119,907			117,418
Construction in progress	2,164			2,396
Property and equipment, at cost	296,155			290,640
Less: Accumulated depreciation	(91,486		)	(86,387		)
Property and equipment, net	$	204,669		$	204,253

Schedule of Finite-Lived Intangible Assets

A summary of the activity related to intangible assets for the three months ended March 31, 2017 follows (in thousands):



	Physician Income Guarantees			Management Rights			Non-Compete Agreements			Certificates of Need		Customer Relationships			Other			Total Intangible Assets

Balance at December 31, 2016	$	813		$	21,290		$	16,457		$	3,780	$	3,704		$	1,979		$	48,023
Additions	175			—			—			14		—			—			189
Recruitment expense	(142		)	—			—			—		—			—			(142		)
Amortization	—			(433		)	(1,414		)	—		(275		)	(195		)	(2,317		)
Balance at March 31, 2017	$	846		$	20,857		$	15,043		$	3,794	$	3,429		$	1,784		$	45,753

Schedule of Indefinite-Lived Intangible Assets

A summary of the activity related to intangible assets for the three months ended March 31, 2017 follows (in thousands):



	Physician Income Guarantees			Management Rights			Non-Compete Agreements			Certificates of Need		Customer Relationships			Other			Total Intangible Assets

Balance at December 31, 2016	$	813		$	21,290		$	16,457		$	3,780	$	3,704		$	1,979		$	48,023
Additions	175			—			—			14		—			—			189
Recruitment expense	(142		)	—			—			—		—			—			(142		)
Amortization	—			(433		)	(1,414		)	—		(275		)	(195		)	(2,317		)
Balance at March 31, 2017	$	846		$	20,857		$	15,043		$	3,794	$	3,429		$	1,784		$	45,753

Schedule of Rollforward of Goodwill

A summary of activity related to goodwill for the three months ended March 31, 2017 follows (in thousands):



Balance at December 31, 2016	$	1,555,204
Acquisitions	11
Purchase price adjustments	1,289
Balance at March 31, 2017	$	1,556,504

Schedule of Other Long-Term Assets

A summary of other long-term assets follows (in thousands):



	March 31, 2017		December 31, 2016

Notes receivable	$	704	$	716
Deposits	3,812		4,196
Assets of SERP	1,834		1,725
Debt issuance costs	1,343		1,488
Insurance recoverable	6,835		6,835
Other	1,446		1,475
Total	$	15,974	$	16,435

Schedule of Other Current Liabilities

A summary of other current liabilities follows (in thousands):



	March 31, 2017		December 31, 2016

Interest payable	$	27,592	$	19,206
Current taxes payable	3,104		2,622
Insurance liabilities	6,932		6,625
Third-party settlements	1,137		179
Amounts due to patients and payors	14,636		12,221
Tax receivable agreement liability	999		999
Contingent acquisition compensation liability	6,119		4,589
Other accrued expenses	23,194		22,552
Total	$	83,713	$	68,993

Schedule of Other Long-Term Liabilities

A summary of other long-term liabilities follows (in thousands):



	March 31, 2017		December 31, 2016

Facility lease obligations	$	52,284	$	52,653
Medical malpractice liability	10,453		10,453
Liability of SERP	1,834		1,725
Unfavorable lease liability	1,590		1,671
Other long-term liabilities	9,728		9,764
Total	$	75,889	$	76,266

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2017

Debt Disclosure [Abstract]

Summary of long-term debt

A summary of long-term debt follows (in thousands):



	March 31, 2017			December 31, 2016

2014 Revolver Loan	$	69,000		$	85,000
2014 First Lien Credit Agreement	929,625			932,000
Senior Unsecured Notes	400,000			400,000
Subordinated Notes	1,000			1,000
Notes payable and secured loans	40,808			42,521
Capital lease obligations	14,860			13,996
Less: unamortized debt issuance costs and discount	(30,529		)	(32,274		)
Total debt	1,424,764			1,442,243
Less: Current maturities	28,722			27,822
Total long-term debt	$	1,396,042		$	1,414,421

Debt redemption percentages

The Company may redeem the Senior Unsecured Notes, in whole or in part, at any time on or after April 15, 2018, plus accrued and unpaid interest, if any, to the date of redemption plus a redemption price equal to a percentage of the principal amount of the notes redeemed based on the following redemption schedule:



April 15, 2018 to April 14, 2019	106.656	%
April 15, 2019 to April 14, 2020	104.438	%
April 15, 2020 and thereafter	100.000	%

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following is a reconciliation of the numerator and denominator of basic and diluted earnings per share for the three months ended March 31, 2017 and 2016 (in thousands except share and per share amounts):



	Three Months Ended March 31,
	2017			2016

Numerator:
Net loss attributable to Surgery Partners, Inc.	$	(2,754	)	$	(7,190	)

Denominator:
Weighted average shares outstanding- basic	48,019,652			48,017,226
Effect of dilutive securities ⁽¹⁾	—			—
Weighted average shares outstanding- diluted	48,019,652			48,017,226

Earnings (loss) per share:
Basic	$	(0.06	)	$	(0.15	)
Diluted ⁽¹⁾	$	(0.06	)	$	(0.15	)

Dilutive securities outstanding not included in the computation of earnings (loss) per share as their effect is antidilutive:
Stock options	851			8,488
Restricted shares	132,485			204,437

⁽¹⁾The impact of potentially dilutive securities for the three months ended March 31, 2017 and 2016 was not considered because the effect would be anti-dilutive in those periods.

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Reconciliation of Revenue from Segments to Consolidated

The following tables present financial information for each reportable segment (in thousands):



	Three Months Ended March 31,
	2017		2016
Revenues:
Surgical facility services	$	258,149	$	245,670
Ancillary services	25,212		17,780
Optical services	2,822		3,624
Total revenues	$	286,183	$	267,074

Schedule of Segment Operating Income



	Three Months Ended March 31,
	2017			2016
Segment Adjusted EBITDA:
Surgical facility services	$	48,241		$	45,661
Ancillary services	3,782			3,500
Optical services	776			879
Total segment adjusted EBITDA ⁽¹⁾	$	52,799		$	50,040

General and administrative expenses	$	(15,541	)	$	(12,197	)
Non-cash stock compensation expense	634			133
Contingent acquisition compensation expense	2,033			—
Acquisition related costs	182			450
Total adjusted EBITDA ⁽¹⁾	40,107			38,426

Net income attributable to non-controlling interests	17,176			17,547
Depreciation and amortization	(11,108		)	(9,568		)
Interest and other expense, net	(25,182		)	(22,153		)
Income tax expense	(2,117		)	(1,770		)
Non-cash stock compensation expense	(634		)	(133		)
Contingent acquisition compensation expense	(2,033		)	—
Merger transaction, integration and practice acquisition costs ⁽²⁾	(591		)	(3,917		)
(Loss) gain on disposal or impairment of long-lived assets, net	(1,196		)	206
Loss on debt refinancing	—			(8,281		)
Total net income	$	14,422		$	10,357

⁽¹⁾The above table reconciles adjusted EBITDA by segment to net income as reflected in the unaudited condensed consolidated statements of operations.

Reconciliation of Assets from Segment to Consolidated



	March 31, 2017		December 31, 2016
Assets:
Surgical facility services	$	1,904,858	$	1,914,842
Ancillary services	187,499		184,002
Optical services	23,884		22,478
Total	2,116,241		2,121,322

General and administrative	$	173,492	$	183,636
Total assets	$	2,289,733	$	2,304,958

Schedule of Other Segment Reporting Information



	Three Months Ended March 31,
	2017		2016
Supplemental Information:
Cash purchases of property and equipment, net:
Surgical facility services	$	4,417	$	9,815
Ancillary services	1,511		560
Optical services	18		77
Total	$	5,946	$	10,452

General and administrative	$	404	$	1,352
Total cash purchases of property and equipment, net	$	6,350	$	11,804

Organization (Details)	Oct. 01, 2015 $ / shares shares	Mar. 31, 2017 surgical_facility state shares	Dec. 31, 2016 shares	Sep. 30, 2015 shares
Product Information [Line Items]
Common stock, shares issued (shares) \| shares		48,782,362	48,488,616
Number of States in which entity operates \| state		29
Number of surgical facilities owned		104
Number of surgical facilities owned, majority interest		74
Number of surgical facilities owned, consolidated		94
Facilities, Ambulatory Surgery Centers
Product Information [Line Items]
Number of surgical facilities owned		99
Facilities, Surgical Hospitals
Product Information [Line Items]
Number of surgical facilities owned		5
Facilities, Physician Clinics
Product Information [Line Items]
Number of surgical facilities owned		56
Surgery Center Holdings, LLC
Product Information [Line Items]
Common stock, shares issued (shares) \| shares				33,871,990
IPO
Product Information [Line Items]
Stock issued during period (shares) \| shares	14,285,000
Share price (in USD per share) \| $ / shares	$ 19.00

Significant Accounting Policies - Schedule of Non-Controlling Interests - Redeemable (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Non-Controlling Interests - Redeemable [Roll Forward]
Beginning balance	$ 180,521
Net income attributable to non-controlling interests—redeemable	3,786
Acquisition and disposal of shares of non-controlling interests, net—redeemable	(710)
Distributions to non-controlling interest —redeemable holders	(4,208)
Ending balance	$ 179,389

Significant Accounting Policies - Variable Interest Entities (Details) $ in Millions	3 Months Ended			12 Months Ended
	Mar. 31, 2017 USD ($) Anesthesia_Practice	Mar. 31, 2017 USD ($) surgical_facility	Mar. 31, 2017 USD ($) Practice	Dec. 31, 2016 USD ($) Anesthesia_Practice	Dec. 31, 2016 USD ($) surgical_facility	Dec. 31, 2016 USD ($) Practice
Variable Interest Entity [Line Items]
Number of facilities included in VIE	3	5	2	3	5	2
Variable Interest Entity, Primary Beneficiary, Aggregated Disclosure
Variable Interest Entity [Line Items]
Total assets related to VIE	$ 96.7	$ 96.7	$ 96.7	$ 99.5	$ 99.5	$ 99.5
Total liabilities related to VIE	$ 12.0	$ 12.0	$ 12.0	$ 10.7	$ 10.7	$ 10.7

Significant Accounting Policies - Equity Method Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investments in and advances to affiliates	$ 35,114	$ 34,980

Significant Accounting Policies - Schedule of Carrying Amount and Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Senior Unsecured Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	$ 400,000	$ 400,000
Carrying Amount \| Senior Unsecured Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	388,511	387,942
Fair Value \| Senior Unsecured Notes \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	409,393	412,189
2014 First Lien Credit Agreement \| Line of Credit
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	929,625	932,000
2014 First Lien Credit Agreement \| Carrying Amount \| Line of Credit
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	910,584	911,784
2014 First Lien Credit Agreement \| Fair Value \| Line of Credit \| Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	$ 920,264	$ 917,528

Significant Accounting Policies - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets of SERP	$ 1,834	$ 1,725
Liability of SERP	1,834	1,725
Fair Value, Inputs, Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets of SERP	1,800	1,700
Liability of SERP	$ 1,800	$ 1,700

Significant Accounting Policies - Schedule of Revenues by Service Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue from External Customer [Line Items]
Increase of revenue as result of changes in estimates to third-party settlements related to prior years	$ 378
Revenue Source \| Revenue
Revenue from External Customer [Line Items]
Service revenues as a percentage of total revenues	100.00%	100.00%
Revenue Source \| Revenue \| Healthcare Organization, Patient Service
Revenue from External Customer [Line Items]
Service revenues as a percentage of total revenues	98.40%	97.90%
Revenue Source \| Revenue \| Surgical Facility Services
Revenue from External Customer [Line Items]
Service revenues as a percentage of total revenues	89.60%	91.30%
Revenue Source \| Revenue \| Ancillary Services
Revenue from External Customer [Line Items]
Service revenues as a percentage of total revenues	8.80%	6.60%
Revenue Source \| Revenue \| Healthcare Organization, Other Service
Revenue from External Customer [Line Items]
Service revenues as a percentage of total revenues	1.60%	2.10%
Revenue Source \| Revenue \| Optical Services
Revenue from External Customer [Line Items]
Service revenues as a percentage of total revenues	1.00%	1.40%
Revenue Source \| Revenue \| Other
Revenue from External Customer [Line Items]
Service revenues as a percentage of total revenues	0.60%	0.70%

Significant Accounting Policies - Schedule of Revenues by Sources (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Total net revenues	$ 286,183	$ 267,074
Healthcare Organization, Patient Service
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Patient service revenues	$ 281,646	$ 261,560
Healthcare Organization, Patient Service \| Customer \| Revenue
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Service revenues as a percentage of total revenues	100.00%	100.00%
Healthcare Organization, Patient Service \| Private insurance
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Patient service revenues	$ 139,003	$ 132,215
Healthcare Organization, Patient Service \| Private insurance \| Customer \| Revenue
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Service revenues as a percentage of total revenues	49.40%	50.50%
Healthcare Organization, Patient Service \| Government
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Patient service revenues	$ 116,878	$ 105,803
Healthcare Organization, Patient Service \| Government \| Customer \| Revenue
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Service revenues as a percentage of total revenues	41.50%	40.50%
Healthcare Organization, Patient Service \| Self-pay
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Patient service revenues	$ 6,071	$ 3,713
Healthcare Organization, Patient Service \| Self-pay \| Customer \| Revenue
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Service revenues as a percentage of total revenues	2.20%	1.40%
Healthcare Organization, Patient Service \| Other
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Patient service revenues	$ 19,694	$ 19,829
Healthcare Organization, Patient Service \| Other \| Customer \| Revenue
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Service revenues as a percentage of total revenues	6.90%	7.60%
Optical Services
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Other service revenues	$ 2,821	$ 3,624
Other
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Other service revenues	$ 1,716	$ 1,890

Significant Accounting Policies - Accounts Receivable (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Third-Party Medicaid settlement net liability	$ 503,000
Third-Party Medicaid settlement receivable		$ 454,000
Optical products receivable	$ 8,936,000	$ 7,042,000

Significant Accounting Policies - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid expenses	$ 14,024	$ 11,158
Receivables - optical product purchasing organization	8,936	7,042
Insurance recoveries	2,315	2,476
Other current assets	10,604	11,338
Total	$ 35,879	$ 32,014

Significant Accounting Policies - Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Schedule of Property, Plant and Equipment
Property and equipment, gross	$ 296,155	$ 290,640
Less: accumulated depreciation	(91,486)	(86,387)
Property and equipment, net	204,669	204,253
Carrying value of assets under capital lease	16,400	15,400
Accumulated depreciation of assets under capital lease	(11,400)	(11,600)
Land
Schedule of Property, Plant and Equipment
Property and equipment, gross	8,082	8,082
Buildings and improvements
Schedule of Property, Plant and Equipment
Property and equipment, gross	120,443	118,172
Furniture and equipment
Schedule of Property, Plant and Equipment
Property and equipment, gross	$ 14,959	14,670
Furniture and equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property, and equipment useful life	5 years
Furniture and equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property, and equipment useful life	7 years
Computer and software
Schedule of Property, Plant and Equipment
Property and equipment, gross	$ 30,600	29,902
Computer and software \| Minimum
Property, Plant and Equipment [Line Items]
Property, and equipment useful life	3 years
Computer and software \| Maximum
Property, Plant and Equipment [Line Items]
Property, and equipment useful life	5 years
Medical equipment
Schedule of Property, Plant and Equipment
Property and equipment, gross	$ 119,907	117,418
Construction in progress
Schedule of Property, Plant and Equipment
Property and equipment, gross	$ 2,164	$ 2,396

Significant Accounting Policies - Schedule of Intangible Assets (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Intangible Assets [Roll Forward]
Beginning balance	$ 48,023
Additions	189
Recruitment expense	(142)
Amortization	(2,317)
Ending balance	45,753
Certificates of Need
Intangible Assets [Roll Forward]
Beginning balance	3,780
Additions	14
Ending balance	3,794
Physician Income Guarantees
Intangible Assets [Roll Forward]
Beginning balance	813
Additions	175
Recruitment expense	(142)
Ending balance	$ 846
Physician Income Guarantees \| Minimum
Intangible Assets [Line Items]
Intangible asset useful life	3 years
Physician Income Guarantees \| Maximum
Intangible Assets [Line Items]
Intangible asset useful life	4 years
Non-Compete Agreements
Intangible Assets [Roll Forward]
Beginning balance	$ 16,457
Additions	0
Amortization	(1,414)
Ending balance	$ 15,043
Non-Compete Agreements \| Minimum
Intangible Assets [Line Items]
Intangible asset useful life	2 years
Non-Compete Agreements \| Maximum
Intangible Assets [Line Items]
Intangible asset useful life	20 years
Management Rights
Intangible Assets [Line Items]
Intangible asset useful life	15 years
Intangible Assets [Roll Forward]
Beginning balance	$ 21,290
Additions	0
Amortization	(433)
Ending balance	20,857
Customer Relationships
Intangible Assets [Roll Forward]
Beginning balance	3,704
Additions	0
Amortization	(275)
Ending balance	$ 3,429
Customer Relationships \| Minimum
Intangible Assets [Line Items]
Intangible asset useful life	3 years
Customer Relationships \| Maximum
Intangible Assets [Line Items]
Intangible asset useful life	10 years
Other
Intangible Assets [Roll Forward]
Beginning balance	$ 1,979
Additions	0
Amortization	(195)
Ending balance	$ 1,784

Significant Accounting Policies - Schedule of Rollforward of Goodwill (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 1,555,204
Acquisitions	11
Purchase price adjustments	1,289
Goodwill, end of period	$ 1,556,504

Significant Accounting Policies - Restricted Invested Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted invested assets	$ 315	$ 315
Chesterfield, Missouri facility
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted invested assets	$ 315	$ 315

Significant Accounting Policies - Schedule of Other Long-Term Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Notes receivable	$ 704	$ 716
Deposits	3,812	4,196
Assets of SERP	1,834	1,725
Debt issuance costs	1,343	1,488
Insurance recoverable	6,835	6,835
Other	1,446	1,475
Total	$ 15,974	$ 16,435

Significant Accounting Policies - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Capital Leased Assets [Line Items]
Capital lease obligations	$ 14,860	$ 13,996
Other Liabilities, Current [Abstract]
Interest payable	27,592	19,206
Current taxes payable	3,104	2,622
Insurance liabilities	6,932	6,625
Third-party settlements	1,137	179
Amounts due to patients and payors	14,636	12,221
Tax receivable agreement liability	999	999
Contingent acquisition compensation liability	6,119	4,589
Other accrued expenses	23,194	22,552
Total	83,713	68,993
Idaho Falls, Idaho, Surgical Hospital
Capital Leased Assets [Line Items]
Capital lease obligations	49,800	50,000
Current portion of lease obligation	1,200	1,100
Ocala, Florida
Capital Leased Assets [Line Items]
Capital lease obligations	3,700	3,700
Current portion of lease obligation	$ 185	$ 182

Significant Accounting Policies - Schedule of Other Long-Term Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Facility lease obligations	$ 52,284	$ 52,653
Medical malpractice liability	10,453	10,453
Liability of SERP	1,834	1,725
Unfavorable lease liability	1,590	1,671
Other long-term liabilities	9,728	9,764
Total	75,889	76,266
Capital Leased Assets [Line Items]
Capital lease obligations	14,860	13,996
Idaho Falls, Idaho, Surgical Hospital
Capital Leased Assets [Line Items]
Current portion of lease obligation	1,200	1,100
Capital lease obligations	49,800	50,000
Ocala, Florida
Capital Leased Assets [Line Items]
Current portion of lease obligation	185	182
Capital lease obligations	$ 3,700	$ 3,700

Significant Accounting Policies - Professional, General and Workers' Compensation Insurance (Details) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Professional, general and workers' compensation insurance reserve	$ 13.5	$ 13.8
Estimated insurance recoveries	$ 9.2	$ 9.3

Significant Accounting Policies - Income Taxes and Tax Receivable Agreement (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Sep. 30, 2015
Income Tax Contingency [Line Items]
Percentage of cash savings requited to pay Tax Receivables Agreement		85.00%
Long-term tax receivable agreement liability	$ 123.4
LIBOR
Income Tax Contingency [Line Items]
Interest accrued on payment under Tax Receivable Agreement, basis spread on variable rate	3.00%

Long-Term Debt - Summary of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Capital lease obligations	$ 14,860	$ 13,996
Less: unamortized debt issuance costs and discount	(30,529)	(32,274)
Debt and capital lease obligations	1,424,764	1,442,243
Less: Current maturities	28,722	27,822
Total long-term debt	1,396,042	1,414,421
Line of Credit \| 2014 Revolver Loan
Debt Instrument [Line Items]
Long-term debt	69,000	85,000
Line of Credit \| 2014 First Lien Credit Agreement
Debt Instrument [Line Items]
Long-term debt	929,625	932,000
Senior Unsecured Notes
Debt Instrument [Line Items]
Long-term debt	400,000	400,000
Subordinated Notes
Debt Instrument [Line Items]
Long-term debt	1,000	1,000
Notes payable and secured loans
Debt Instrument [Line Items]
Long-term debt	$ 40,808	$ 42,521

Long-Term Debt - 2014 Revolver Loan (Details) - Line of Credit - USD ($)	3 Months Ended
	Mar. 31, 2017	Oct. 07, 2015	Nov. 03, 2014
2014 Revolver Loan
Debt Instrument [Line Items]
Debt maximum borrowing capacity		$ 150,000,000.0	$ 80,000,000.0
Quarterly commitment fee percentage	0.50%
Debt remaining borrowing capacity	$ 77,900,000
2014 Revolver Loan \| Alternate Base Rate Loan
Debt Instrument [Line Items]
Debt instrument, margin in addition to base rate	3.25%
2014 Revolver Loan \| Alternate Base Rate Loan \| Federal Funds Effective Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.50%
2014 Revolver Loan \| Alternate Base Rate Loan \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.00%
2014 Revolver Loan \| Eurodollar Loan
Debt Instrument [Line Items]
Debt instrument, margin in addition to base rate	4.25%
Letters of Credit
Debt Instrument [Line Items]
Debt remaining borrowing capacity	$ 3,100,000

Long-Term Debt - 2014 First Lien Credit Agreement (Details) - 2014 First Lien Credit Agreement - Line of Credit - USD ($)		3 Months Ended
	Sep. 26, 2016	Mar. 31, 2017	Mar. 24, 2016
Debt Instrument [Line Items]
Debt instrument, increase in maximum borrowing capacity			$ 80,000,000.0
Debt maximum borrowing capacity			$ 950,000,000.0
Debt instrument, threshold business days in certain condition to make mandatory interest payment		5 days
Debt Instrument, number of days after each fiscal year in certain condition to make mandatory interest payment		90 days
Alternate Base Rate Loan
Debt Instrument [Line Items]
Debt instrument, margin in addition to base rate	2.75%	2.75%
Debt instrument, maximum base rate condition		2.00%
Alternate Base Rate Loan \| Federal Funds Effective Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.50%
Alternate Base Rate Loan \| LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.00%
Eurodollar Loan
Debt Instrument [Line Items]
Debt instrument, margin in addition to base rate	3.75%	3.75%
Debt instrument, maximum base rate condition		1.00%

Long-Term Debt - 2014 Second Lien Credit Agreement (Details) - USD ($) $ in Thousands		3 Months Ended
	Mar. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Loss on debt refinancing		$ 0	$ 8,281
2014 Second Lien Credit Agreement \| Line of Credit
Debt Instrument [Line Items]
Line of credit, repayments	$ 252,800
Accrued interest repaid	1,300
Loss on debt refinancing	$ 8,300

Long-Term Debt - Senior Unsecured Notes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Debt issuance costs	$ 1,343,000	$ 1,488,000
Senior Unsecured Notes
Debt Instrument [Line Items]
Debt, face amount			$ 400,000,000.0
Debt instrument, stated rate	8.875%
Senior Unsecured Notes \| Before April 15, 2018
Debt Instrument [Line Items]
Debt instrument, redeemable percentage of aggregate principal	35.00%
Redemption price, percentage of principal, proceeds from equity offerings	108.875%
Required remaining principal balance, after redemption	50.00%
Debt redemption, required period after closing of equity offering	180 days
Redemption price, percentage of principal	100.00%
Senior Unsecured Notes \| April 15, 2018 to April 14, 2019
Debt Instrument [Line Items]
Redemption price, percentage of principal	106.656%
Senior Unsecured Notes \| April 15, 2019 to April 14, 2020
Debt Instrument [Line Items]
Redemption price, percentage of principal	104.438%
Senior Unsecured Notes \| April 15, 2020 and thereafter
Debt Instrument [Line Items]
Redemption price, percentage of principal	100.00%
Senior Unsecured Notes \| Change in control
Debt Instrument [Line Items]
Redemption price, percentage of principal	101.00%
Debt issuance costs			$ 8,400,000

Long-Term Debt - Additional (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016	Apr. 11, 2013
Debt Instrument [Line Items]
Capital leased assets	$ 16,400,000	$ 15,400,000
Subordinated Notes
Debt Instrument [Line Items]
Debt maximum borrowing capacity			$ 1,000,000.0
Debt instrument, stated rate	17.00%
Long-term debt, carrying value	$ 1,000,000	1,000,000
Notes payable and secured loans
Debt Instrument [Line Items]
Long-term debt, carrying value	$ 40,808,000	$ 42,521,000

Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Numerator:

Net loss attributable to Surgery Partners, Inc.

$ (2,754)

$ (7,190)

Denominator:

Weighted average shares outstanding- basic (shares)

48,019,652

48,017,226

Effect of dilutive securities (shares)

Weighted average shares outstanding- diluted (shares)

^[1]

48,019,652

48,017,226

Earnings (loss) per share:

Basic earnings per share (in USD per share)

$ (0.06)

$ (0.15)

Diluted earnings per share (in USD per share)

^[1]

$ (0.06)

$ (0.15)

Stock options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings (loss) per share (shares)

851

8,488

Restricted shares

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of earnings (loss) per share (shares)

132,485

204,437

[1]	The impact of potentially dilutive securities for the three months ended March 31, 2017 and 2016 was not considered because the effect would be anti-dilutive in those periods.

Commitments and Contingencies (Details) - Purchase Agreement	Apr. 20, 2017 USD ($)	Dec. 24, 2009 USD ($) Entity
Guarantor Obligations [Line Items]
Number of business entities acquired \| Entity		36
Maximum potential contingent consideration		$ 10,000,000.0
Subsequent Event
Guarantor Obligations [Line Items]
Total settlement amount	$ 3,900,000
Amount of settlement paid from escrow	2,700,000
Amount of settlement paid by seller	$ 1,200,000

Segment Reporting - Revenues by Reportable Segment (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017 USD ($) segment	Mar. 31, 2016 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments \| segment	3
Revenues	$ 286,183	$ 267,074
Surgical Facility Services
Segment Reporting Information [Line Items]
Revenues	258,149	245,670
Ancillary Services
Segment Reporting Information [Line Items]
Revenues	25,212	17,780
Optical Services
Segment Reporting Information [Line Items]
Revenues	$ 2,822	$ 3,624

Segment Reporting - Segment Operating Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Total segment adjusted EBITDA	$ 40,107	$ 38,426
General and administrative expenses	(15,541)	(12,197)
Non-cash stock compensation expense	634	133
Contingent acquisition compensation expense	2,033	0
Acquisition related costs	182	450
Total segment adjusted EBITDA	40,107	38,426
Net income attributable to non-controlling interests	17,176	17,547
Depreciation and amortization	(11,108)	(9,568)
Interest and other expense, net	(25,182)	(22,153)
Income tax expense	(2,117)	(1,770)
Non-cash stock compensation expense	(634)	(133)
Contingent acquisition compensation expense	(2,033)	0
Merger transaction, integration and practice acquisition costs	(591)	(3,917)
(Loss) gain on disposal or impairment of long-lived assets, net	(1,196)	206
Loss on debt refinancing	0	(8,281)
Net income	14,422	10,357
Merger transaction and integration costs	337	3,172
Practice acquisition costs	254	745
Operating Segments
Segment Reporting Information [Line Items]
Total segment adjusted EBITDA	52,799	50,040
Total segment adjusted EBITDA	52,799	50,040
Operating Segments \| Surgical Facility Services
Segment Reporting Information [Line Items]
Total segment adjusted EBITDA	48,241	45,661
Total segment adjusted EBITDA	48,241	45,661
Operating Segments \| Ancillary Services
Segment Reporting Information [Line Items]
Total segment adjusted EBITDA	3,782	3,500
Total segment adjusted EBITDA	3,782	3,500
Operating Segments \| Optical Services
Segment Reporting Information [Line Items]
Total segment adjusted EBITDA	776	879
Total segment adjusted EBITDA	$ 776	$ 879

Segment Reporting - Assets by Operating Segment (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Segment Reporting Information [Line Items]
Assets	$ 2,289,733	$ 2,304,958
Operating Segments
Segment Reporting Information [Line Items]
Assets	2,116,241	2,121,322
Operating Segments \| Surgical Facility Services
Segment Reporting Information [Line Items]
Assets	1,904,858	1,914,842
Operating Segments \| Ancillary Services
Segment Reporting Information [Line Items]
Assets	187,499	184,002
Operating Segments \| Optical Services
Segment Reporting Information [Line Items]
Assets	23,884	22,478
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Assets	$ 173,492	$ 183,636

Segment Reporting - Cash Purchases of Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Purchases of property and equipment, net	$ 6,350	$ 11,804
Operating Segments
Segment Reporting Information [Line Items]
Purchases of property and equipment, net	5,946	10,452
Operating Segments \| Surgical Facility Services
Segment Reporting Information [Line Items]
Purchases of property and equipment, net	4,417	9,815
Operating Segments \| Ancillary Services
Segment Reporting Information [Line Items]
Purchases of property and equipment, net	1,511	560
Operating Segments \| Optical Services
Segment Reporting Information [Line Items]
Purchases of property and equipment, net	18	77
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Purchases of property and equipment, net	$ 404	$ 1,352

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	May 09, 2017	Apr. 20, 2017	Mar. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Preferred stock, par value (in USD per share)			$ 0.01	$ 0.01
Subsequent Event \| Majority Shareholder \| BCPE Seminole Holdings LP
Subsequent Event [Line Items]
Stock expected to be sold by investor (in shares)	26,455,651
Stock expected to be sold by investor, price per share (in USD per share)	$ 19.00
Subsequent Event \| Purchase Agreement
Subsequent Event [Line Items]
Gain on litigation settlement		$ 3.9
Subsequent Event \| NSH
Subsequent Event [Line Items]
Business combination, expected consideration	$ 760.0
Preferred Class A \| Preferred Stock \| Subsequent Event \| BCPE Seminole Holdings LP
Subsequent Event [Line Items]
Preferred stock, par value (in USD per share)	$ 0.01
Preferred stock dividend rate	10.00%
Preferred Class A \| Preferred Stock \| Maximum \| Subsequent Event \| BCPE Seminole Holdings LP
Subsequent Event [Line Items]
Stock expected to be issued (in shares)	320,000